Richard Miller

“We are highly focused on Soqualitinib, our first-in-class selective ITK inhibitor.”

“I'm delighted to be able to give you an update on Corvus Pharmaceuticals. In particular, I'm going to be covering some data that was presented at the Society of Investigative Dermatology meeting a couple of weeks ago.”

“We are very eager today to present the results from our Phase I clinical trial with socolitinib in atopic dermatitis. The data reinforced that socolitinib is a first-in-class oral drug that represents a potential significant breakthrough for the treatment of atopic dermatitis and other immune diseases.”

“In 2025, we made significant progress advancing the development of socolitinib, our first in class selective ITK inhibitor that is designed to rebalance or reset the immune system.”

“Our primary focus continues to be on the development of soqualitinib for both atopic dermatitis and T-cell lymphomas, and we have several important milestones upcoming for these programs.”